43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Humanistic burden in schizophrenia: a literature review.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Schizophrenia is a complex disease that affects 1% of the population. This disease has a considerable impact not only on patients' health and well-being but also on their surrounding environment. The costs of the disease's management remain large for individuals and society. While literature on the economic impact of schizophrenia is abundant, few studies have focused on its humanistic burden. This does not only concern patients, but also caregivers, relatives, neighbours and others in a patient's daily life. This burden appears through several dimensions, including treatment side effects and the impact on caregivers and features of the patient's environment. The aim of this review is to consider, compile and describe the humanistic burden of schizophrenia as documented in the literature.

          Related collections

          Author and article information

          Journal
          J Psychiatr Res
          Journal of psychiatric research
          1879-1379
          0022-3956
          Jul 2014
          : 54
          Affiliations
          [1 ] Creativ-Ceutical, Paris, France. Electronic address: ami@creativ-ceutical.com.
          [2 ] Creativ-Ceutical, Luxembourg, Luxembourg. Electronic address: usc@creativ-ceutical.com.
          [3 ] Center for Public Mental Health, Gösing am Wagram, Austria; Department of Public Health and Clinical and Molecular Medicine, University of Cagliari, Italy. Electronic address: angermeyer@aon.at.
          [4 ] Takeda Pharmaceuticals, London, England, United Kingdom. Electronic address: d.chauhan@tgrd.com.
          [5 ] Takeda Pharmaceuticals, London, England, United Kingdom. Electronic address: venkatesha.murthy@takeda.com.
          [6 ] University Claude Bernard Lyon I, UFR d'Odontologie 11, rue Guillaume Paradin, 69372 Lyon CEDEX 08, France. Electronic address: Mondher.toumi@univ-lyon1.fr.
          [7 ] Takeda Pharmaceuticals, Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland. Electronic address: nadia.cadi-soussi@takeda.com.
          Article
          S0022-3956(14)00103-4
          10.1016/j.jpsychires.2014.03.021
          24795289
          51a5461c-f4d3-4417-867e-32d013f50fb2
          Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
          History

          Antipsychotics,Disease burden,Humanistic burden,Schizophrenia

          Comments

          Comment on this article